- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Niagen Bioscience, Inc.(NAGE)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for NAGE
11/13/2026: NAGE (2-star) is currently NOT-A-BUY. Pass it for now.
Niagen Bioscience, Inc. is a bioscience company specializing in NAD+ research and healthy-aging supplements, best known for its Tru Niagen® product and patented ingredient. The company has successfully transitioned from an ingredient service provider into a consumer-focused longevity brand with promising pharmaceutical ambitions. While its patented technology and strong branding are key strengths, the company faces risks related to competition and the need for ongoing clinical validation of its proprietary molecules. It may suit growth-oriented investors interested in the longevity space. Future developments in its pharmaceutical pipeline and international channel expansion remain critical areas for monitoring.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company's expansion into pharmaceuticals and new consumer segments offers significant upside potential. |
| Momentum investor | Strong fit while signal remains positive | The stock often reacts to new clinical findings or patent announcements, suiting traders tracking positive catalysts. |
| Value investor | Mixed fit | Valuation fluctuates based on long-term growth expectations rather than current yield. |
| Dividend investor | Weak fit | The company does not pay dividends, prioritizing capital reinvestment. |
| Low-risk investor | Weak fit | The company's focus on emerging science creates higher price volatility. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock's dependence on clinical trial results and scientific sentiment leads to significant price swings. |
| Valuation risk | Medium / high | Market pricing is sensitive to future growth projections in the competitive longevity sector. |
| Competition risk | Medium / high | The supplement market is highly fragmented with frequent new competitors. |
| Business quality | Medium | The company has established a credible science-backed brand but is still scaling. |
| Dividend income | Low / none | Investors should not expect income, as capital is reinvested in R&D. |
| Execution risk | Medium | Success depends heavily on the commercialization of its pharmaceutical pipeline. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 163.54M USD | Price to earnings Ratio 17.21 | 1Y Target Price 10.67 |
Price to earnings Ratio 17.21 | 1Y Target Price 10.67 | ||
Volume (30-day avg) 527.6K shares | Beta 2.08 | 52 Weeks Range 2.04 - 7.12 | Updated Date 11/14/2026 |
52 Weeks Range 2.04 - 7.12 | Updated Date 11/14/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.12 |
Sector & Industry Intelligence
Sector
Consumer Defensive
Defensive- Sentiment
- Correction Expected
- Momentum
- BUY Breadth Improving
- BUY participation
- 95.0%
- Active BUY / eligible
- 19 / 20
- 30-Day BUY Count Change
- +13
- Market state
- Correction Expected
More qualifying stocks are receiving or maintaining BUY advisories, indicating improving market participation.
Industry
Industry classification is unavailable for this snapshot.
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Steep Decline
The stock price has dropped sharply with strong downward pressure.

Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit 110.13% | Avg. Invested days 34 | Today’s Advisory PASS |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Consumer Products | Direct sales of Tru Niagen® and Niagen Plus® supplements. | This is the primary revenue engine for the company. |
| Ingredients | Wholesale distribution of Niagen® to third-party manufacturers. | Provides a B2B revenue stream that scales with industry adoption of their patented molecule. |
Valuation
Trailing PE 17.21 | Forward PE 42.73 | Enterprise Value 102.05M | Price to Sales(TTM) 1.34 |
Enterprise Value 102.05M | Price to Sales(TTM) 1.34 | ||
Enterprise Value to Revenue 0.83 | Enterprise Value to EBITDA 22.34 | Shares Outstanding 79.20M | Shares Floating 59.15M |
Shares Outstanding 79.20M | Shares Floating 59.15M | ||
Percent Insiders 29.43 | Percent Institutions 41.09 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

